Department of Internal Medicine, University of Health Sciences, Malatya Training and Research Hospital, Malatya, Turkey.
Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5511-5517. doi: 10.26355/eurrev_202109_26662.
We aimed at demonstrating the effect of thyroid function status on proprotein convertase subtilisin kexin type 9 (PCSK9) and determining the effect of thyroid hormones on lipid metabolism by comparing the PCSK9 levels of patients with subclinical hypothyroidism, overt hypothyroidism, and hyperthyroidism.
124 patients with thyroid disorders, aged between 18 and 65 years, were included in this study. The participants were divided into 3 groups. Group 1 comprised 52 patients with subclinical hypothyroidism, Group 2 comprised 40 patients with overt hypothyroidism, and Group 3 comprised 32 patients with hyperthyroidism. In all of these groups, the thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, total cholesterol, fasting serum glucose, antithyroid peroxidase antibody, antithyroglobulin antibody, and PCSK9 levels were measured.
No significant difference was found between the 3 groups in terms of age, gender, and body mass indices. Median PCSK9 measurements were 14.55 ng/mL in Group 1, 14.895 ng/mL in Group 2, and 9.775 ng/mL in Group 3. There was a significant difference in the PCSK9 levels between Group 1-Group 3 and Group 2-Group 3 (p <0.0001 and p <0.0001, respectively). A positive correlation between PCSK9 and the TSH levels (r = 0.211, p= 0.019), and a negative correlation (r = -0,239, p = 0.009 and r = -, 0.218, p = 0.015) between the fT3 and fT4 levels were found.
The serum PCSK9 levels were shown to be associated with thyroid dysfunction. However, no relationship was observed between the serum PCSK9 level and thyroid autoantibody positivity, and obesity in this study.
通过比较亚临床甲状腺功能减退症、显性甲状腺功能减退症和甲状腺功能亢进症患者的 PCSK9 水平，来证明甲状腺功能状态对前蛋白转化酶枯草溶菌素 9（PCSK9）的影响，并确定甲状腺激素对脂代谢的影响。
纳入了 124 名年龄在 18 至 65 岁之间的甲状腺疾病患者，将其分为 3 组。第 1 组包括 52 名亚临床甲状腺功能减退症患者，第 2 组包括 40 名显性甲状腺功能减退症患者，第 3 组包括 32 名甲状腺功能亢进症患者。在所有这些组中，均测量了促甲状腺激素（TSH）、游离三碘甲状腺原氨酸（fT3）、游离甲状腺素（fT4）、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯、总胆固醇、空腹血糖、抗甲状腺过氧化物酶抗体、抗甲状腺球蛋白抗体和 PCSK9 水平。
3 组之间在年龄、性别和体重指数方面无显著差异。第 1 组的 PCSK9 中位数测量值为 14.55ng/mL，第 2 组为 14.895ng/mL，第 3 组为 9.775ng/mL。第 1 组与第 3 组以及第 2 组与第 3 组之间的 PCSK9 水平存在显著差异（p<0.0001 和 p<0.0001）。PCSK9 与 TSH 水平之间存在正相关（r=0.211，p=0.019），而 fT3 和 fT4 水平之间存在负相关（r=-0.239，p=0.009 和 r=-0.218，p=0.015）。
血清 PCSK9 水平与甲状腺功能障碍有关。然而，在本研究中，血清 PCSK9 水平与甲状腺自身抗体阳性和肥胖之间没有观察到关系。
